INFEX Therapeutics, the Alderley Park-based biotech firm focused on innovative drugs for infectious diseases, has secured $9.0M in new investment. The company, which initially built its reputation on acquiring, developing, and licensing therapies for pandemic infections, is now significantly expanding its scope.
This fresh capital will fuel INFEX's push to develop a broader portfolio of new treatments for critical priority infectious diseases. Its mission remains to address unmet patient needs by bringing novel drugs into clinical trials to combat life-threatening infections.
